Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P. Peter B, et al. Among authors: mayerhofer m. J Leukoc Biol. 2014 Jan;95(1):95-104. doi: 10.1189/jlb.1112609. Epub 2013 Sep 19. J Leukoc Biol. 2014. PMID: 24052572
Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPalpha), CD47, and SHP-1.
Florian S, Ghannadan M, Mayerhofer M, Aichberger KJ, Hauswirth AW, Schernthaner GH, Printz D, Fritsch G, Böhm A, Sonneck K, Krauth MT, Müller MR, Sillaber C, Sperr WR, Bühring HJ, Valent P. Florian S, et al. Among authors: mayerhofer m. J Leukoc Biol. 2005 Jun;77(6):984-92. doi: 10.1189/jlb.0604349. Epub 2005 Mar 22. J Leukoc Biol. 2005. PMID: 15784688
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P. Aichberger KJ, et al. Among authors: mayerhofer m. Blood. 2007 Apr 1;109(7):3031-41. doi: 10.1182/blood-2006-07-032714. Blood. 2007. PMID: 17110460 Free article.
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P. Gleixner KV, et al. Among authors: mayerhofer m. Exp Hematol. 2007 Oct;35(10):1510-21. doi: 10.1016/j.exphem.2007.06.005. Epub 2007 Aug 2. Exp Hematol. 2007. PMID: 17681669 Free article.
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P. Aichberger KJ, et al. Among authors: mayerhofer m. Blood. 2009 Dec 17;114(26):5342-51. doi: 10.1182/blood-2008-08-175190. Epub 2009 Oct 22. Blood. 2009. PMID: 19850739 Free article.
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P. Gleixner KV, et al. Among authors: mayerhofer m. Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16. Blood. 2011. PMID: 21680801 Free article.
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.
Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M, Sperr WR, Arock M, Samorapoompichit P, Horny HP, Metcalfe DD. Valent P, et al. Among authors: mayerhofer m. Eur J Clin Invest. 2004 Aug;34 Suppl 2:41-52. doi: 10.1111/j.0960-135X.2004.01369.x. Eur J Clin Invest. 2004. PMID: 15291805 Review.
Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.
Gleixner KV, Mayerhofer M, Vales A, Gruze A, Hörmann G, Cerny-Reiterer S, Lackner E, Hadzijusufovic E, Herrmann H, Iyer AK, Krauth MT, Pickl WF, Marian B, Panzer-Grümayer R, Sillaber C, Maeda H, Zielinski C, Valent P. Gleixner KV, et al. Among authors: mayerhofer m. Curr Cancer Drug Targets. 2009 Aug;9(5):675-89. doi: 10.2174/156800909789057024. Epub 2009 Aug 1. Curr Cancer Drug Targets. 2009. PMID: 19508170
121 results